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province, 27,800 patients are re-
ceiving their HIV treatment 
through adherence clubs, and 
the approach is being adopted in 
other parts of South Africa. The 
program offers a model for treat-
ment in countries with far fewer 
resources.1,4 Similar community 
models of care have been adopted 
in Mozambique and are being pi-
loted by MSF in Malawi and Zim-
babwe, countries with even 
broader treatment coverage for 
their HIV- infected populations 
but with similar challenges when 
it comes to maintaining patients 
in treatment for a lifetime.
Effective, widespread treat-
ment of HIV in Africa was once 
thought to be logistically and 
economically impossible. Pro-
grams in multiple countries are 
showing that it can be done. But 
the problems involve attitudes as 
well as economics and logistics. 
After the adherence-club meeting 
in the small home in Khayelit-
sha, we gather outside. Someone 
asks our gracious host if she can 
take her picture for an article in 
a local magazine. She pauses, 
and for the first time she seems 
uncomfortable. Then she says yes 
to a picture but asks that her 
name not be used. She has wor-
ries about her employment out-
side Khayelitsha. “These things 
can get around. You cannot trust 
what some people out there 
might do.”
Disclosure forms provided by the author 
are available with the full text of this arti-
cle at NEJM.org.
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Treating Millions for HIV
Distribution of Prepacked ART by Club 
Facilitator Fanelwa Gwashu.
Demedicalizing AIDS Prevention and Treatment in Africa
Tom Ellman, M.B., Ch.B.
At the recent World AIDS Day celebrations, national and 
organizational commitments to 
support affected communities, 
meet treatment and prevention 
targets, and expand access to an-
tiretroviral therapy (ART) were 
asserted once again. Yet the real-
ity in much of Africa suggests 
that AIDS is far from over.
Since 2002, ART programs have 
been slowly rolled out in Africa. 
Initially, HIV-infected people had 
to wait until they were seriously 
immunocompromised, with a 
CD4 T-cell count below 200 per 
cubic millimeter, to begin ART. 
The threshold was raised to 350 
and then 500, as the importance 
of earlier initiation of treatment 
was recognized. Improved tools 
and strategies followed, as did 
consensus on treatment guide-
lines and international funding. 
The trajectory toward ending AIDS 
seemed assured, and international 
goals grew from “3 by 5” (treat-
ing 3 million people by 2005), to 
“15 by 15,” to a call from the 
Joint United Nations Program on 
HIV/AIDS for “90-90-90” by 2020: 
90% of people living with HIV 
tested, 90% receiving treatment, 
and 90% with an undetectable 
viral load.
Close examination of the HIV 
epidemic, however, reveals that 
all is not well. In South Africa, 
home to the world’s largest ART 
program, for instance, 25% of 
patients who begin ART are lost 
to follow-up by a year later, and 
in 25% of treated patients, viral 
suppression is not achieved.1 In 
many countries, rates of retention 
in treatment are worsening, the 
incidence of HIV infection among 
young women remains shockingly 
high,2 men are tested and initiate 
treatment late in the course of 
infection and often not until they 
have advanced disease, public-
sector facilities are overloaded 
with patients and plagued by 
medication stock-outs, and donor 
funding has flatlined for the past 
6 years.3 Perhaps most impor-
tant, the activist groups that have 
held governments, health sys-
tems, and the international com-Lyn
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munity accountable are at best 
underfunded and at worst side-
lined, jaded, and mute. South Af-
rica’s Treatment Action Cam-
paign, which played a major role 
in ending denialism and start-
ing the ART rollout in the coun-
try with the largest HIV-positive 
cohort, faces a major funding 
shortfall.4 As one panelist re-
marked at a conference of the 
Southern African HIV Clinicians 
Society last September, “The 
honeymoon is over.”
A major contributor to these 
problems is the burden placed on 
patients and health care facilities 
by the failure to simplify treat-
ment for healthy HIV-positive 
people. Clinics overloaded with 
the healthy are unable to focus 
high-quality care on patients with 
the greatest need.
As guidelines edge closer to 
universal treatment for HIV- 
infected people regardless of 
CD4 count, more people can 
choose to receive ART before they 
develop symptoms. Earlier treat-
ment represents an opportunity 
not only to prevent illness and 
transmission but also to inform 
and empower people living with 
HIV–AIDS while reducing the 
burden on health care systems. 
Rather than seizing this oppor-
tunity by demedicalizing the pro-
vision of ART, however, programs 
are medicalizing HIV infection 
in the healthy.
In most of Africa, despite 
shortages of health workers, ini-
tiating ART in a healthy HIV-
positive adult means the start of 
monthly queues at clinics and 
pharmacies to see overburdened 
medical staff. To obtain treat-
ment, such patients face long 
walks to health centers or high 
transportation costs, hours of 
queuing, and poor, sometimes 
stigmatizing, consultation. Un-
like symptomatic patients, these 
patients see no short-term bene-
fit from treatment. Unsurpris-
ingly, they often adhere poorly 
to ART regimens or rapidly stop 
them altogether. Many health 
care workers believe such pa-
tients should not be offered 
treatment, so that clinic staff 
can concentrate on sick patients.
The experience of Médecins 
sans Frontières and others sug-
gests that the solution is not to 
deny people earlier treatment but 
rather to implement policies and 
strategies that reduce the burden 
associated with their care. Such 
policies and community-based 
models of care are already well 
described,5 endorsed by the 
World Health Organization, and 
included in national guidelines, 
but theoretical commitment to 
them is not matched by funding.
Like other chronic disease 
treatments, ART is best taken at 
home, with pills available 
through repeat prescription at lo-
cal pharmacies or even by mail. 
A viral-load test performed every 
6 or 12 months can inform HIV-
infected people if they’re doing 
well and need no medical care, 
just as glycated hemoglobin tests 
inform diabetic patients.
Healthy patients require com-
munity-based adherence support 
backed up by robust systems for 
monitoring and evaluation, drug 
delivery, and laboratory testing. 
Those in need of medical care — 
for initiation of ART, when sick 
or suffering from medication side 
effects, or because of high viral 
load or low CD4 count — must 
be distinguished from those who 
are not.
Five elements of this ap-
proach are worth highlighting. 
First, drug delivery should be 
patient-centered: it should fit into 
patients’ lives, requiring minimal 
time and being delinked from 
clinical consultation. Stable, 
healthy, HIV-infected people tak-
ing once-daily, low-toxicity regi-
mens could receive refills lasting 
at least 3 months from a facility 
close to their home, with little or 
no queuing. Ideally, various fast-
track options, including commu-
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Dried-Blood-Spot Sampling Technique for Monitoring Viral Load, Thyolo, Malawi.
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nity pharmacies, would be avail-
able. Community ART groups and 
adherence clubs (see the Perspec-
tive article by Campion, pages 
301–303) can further minimize 
the burden, with one person pick-
ing up drugs for several others. 
Such approaches save costs and 
enhance retention and should be-
come the norm rather than the 
exception.
Second, annual viral-load mea-
surement should replace routine 
CD4 testing for stable, healthy 
ART recipients. Such assessment 
provides an objective measure of 
treatment effectiveness and can 
assuage clinicians’ doubts regard-
ing adherence. If a test on dried 
blood spots (with results deliv-
ered directly to patients and cli-
nicians, by text message where 
possible) revealed an undetectable 
viral load (see photo), the patient 
could continue receiving “mini-
mal-burden care,” with an annu-
al clinic visit. A high viral load 
should trigger a counseling inter-
vention to address adherence, ide-
ally at the community level, 
backed up by clinical screening 
and regimen changes as neces-
sary, until the virus is sup-
pressed. It would not necessarily 
mean shifting the patient from 
low-burden care, which could 
further worsen adherence.
Third, monitoring and evalua-
tion are essential for informing 
patients, providers, and the health 
system but have not been adapt-
ed to systems operating outside 
facility-based clinical care. The 
lack of a functional monitoring 
system leads to government and 
donor mistrust of community-
based support and drug-delivery 
strategies, and investment is 
needed to develop integrated sys-
tems. Such systems should also 
support HIV-positive communities 
to monitor the quality of their 
care and hold the government ac-
countable for drug stock-outs or 
other deficiencies.
Fourth, all these activities de-
pend on trained individuals and 
funded, coordinated structures 
operating at the community lev-
el, near where HIV-infected peo-
ple live. Currently, most inter-
ventions depend on volunteers, 
nongovernmental organizations, 
or scarce and underfunded 
health-center outreach and com-
munity health workers. Capacity 
for managing support groups, 
promoting HIV testing and link-
age to care, identifying at-risk 
patients, monitoring effective-
ness, and supporting adherence 
can be established at the com-
munity level, but not without 
support and funding. Such ser-
vices pose no threat to the 
health sector; rather, greater in-
vestment in community capacity 
should be seen as essential to 
population health.
Finally, independent civil- 
society activism, rooted in affect-
ed communities, remains critical 
to sustaining an effective, ac-
countable response to HIV and 
health care in general. Paradoxi-
cally, with successful ART rollout 
has come a decline in communi-
ty activism. Engagement with the 
strategies described here can con-
tribute to stronger community 
structures, but increased funding 
is essential to ensure that HIV 
activists’ voices are heard.
This approach is not a pana-
cea. For many communities, 
treatment coverage remains un-
acceptably low. The very concept 
of “community” varies with the 
context, and community engage-
ment does not reduce govern-
ment’s responsibility to provide 
high-quality clinical care. Efforts 
to strengthen health system ca-
pacity and end the crisis in hu-
man resources for health must 
not be compromised. Nonethe-
less, a shift from facility-based 
medical care to shared responsi-
bility with community-based 
“wellness” support could trans-
form not just the HIV landscape 
but care for noncommunicable 
diseases and health in general.
Perhaps the threat of vast in-
creases in the number of healthy 
people on ART is the impetus 
the health system, policymakers, 
and donors require to match 
their rhetoric with investment. 
Until they do, the 90-90-90 tar-
get, let alone the end of AIDS, 
will remain a pipe dream.
Disclosure forms provided by the author 
are available with the full text of this article 
at NEJM.org.
From the Southern Africa Medical Unit, 
Médecins sans Frontières, Cape Town, South 
Africa.
1. South African National AIDS Council. 
Progress report on national strategic plan for 
HIV, TB and STIs (2012–2016). November 
2014 (http://www.sanac.org.za/publications/
reports/doc_download/106-sanac-progress 
-report-on-the-national-strategic-plan-for-hiv 
-tb-and-stis-2012-2016).
2. Shisana O, Rehle T, Simbayi LC, et al. 
South African national HIV prevalence, inci-
dence and behaviour survey, 2012. Cape 
Town, South Africa: Human Sciences Re-
search Council, 2014.
3. Kaiser Family Foundation. Financing the 
response to HIV in low- and middle-income 
countries: international assistance from do-
nor governments in 2013. July 2014 (https://
kaiserfamilyfoundation.files.wordpress.com/ 
2014/07/7347-10-financing-the-response-to 
-hiv-in-low-and-middle-income-countries 
.pdf).
4. Piot P, Barré-Sinoussi F, Abdool Karim Q, 
et al. Appeal to global donors to save the 
Treatment Action Campaign. Lancet 2014; 
384(9959):e62.
5. Bemelmans M, Baert S, Goemaere E, et al. 
Community-supported models of care for 
people on HIV treatment in sub-Saharan 
Africa. Trop Med Int Health 2014;19:968-77.
DOI: 10.1056/NEJMp1414730
Copyright © 2015 Massachusetts Medical Society.
The New England Journal of Medicine 
Downloaded from nejm.org at NEW YORK UNIVERSITY on January 28, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
